Belgrade University School of Medicine, Clinics for Infectious and Tropical Disease, Belgrade, Serbia.
Biomed Pharmacother. 2013 Jul;67(6):517-20. doi: 10.1016/j.biopha.2013.03.010. Epub 2013 Mar 30.
Despite the fact that the majority of prevalent and incident cases of HCV are associated with intravenous drug use (IVDU), these patients have largely been excluded from HCV care. The aim of this study was to examine the treatment outcome of chronic hepatitis C in IVDUs compared to non-IVDUs.
Patients with chronic hepatitis C (CHC) who initiated and completed combination antiviral therapy with pegilated interferon and ribavirin, at the Hepatology Department of the University Hospital for Infectious and Tropical Diseases in Belgrade, were retrospectively analyzed. The study included a series of 254 patients of which 100 (39.4%) were former IVDU.
Sustained virological response (SVR) was recorded in a total of 172 patients (67.7%). The analyses of the favorable treatment outcome, regarding particular viral genotypes, revealed that among those with genotype 1 and/or 4, including patients with genotype 1 recombinants with genotype 3, SVR was achieved in 114 (63.3%), while it was almost equally distributed between subgroups of former IVDU and all others (P=0.079). Among patients infected with HCV genotypes 2 and/or 3 the SVR rate was as high as 86.6%.
IVDU with CHC infection should be treated with standard combination antiviral therapy for CHC, since the success rate is equal or even better than in non-IVDU patients.
本研究旨在比较静脉吸毒者（IDU）与非 IDU 慢性丙型肝炎（CHC）患者接受聚乙二醇干扰素联合利巴韦林抗病毒治疗的疗效。
对在贝尔格莱德传染病与热带病大学医院肝脏科接受聚乙二醇干扰素联合利巴韦林抗病毒治疗的 CHC 患者进行回顾性分析。该研究共纳入 254 例患者，其中 100 例（39.4%）为 IDU。
共有 172 例患者获得持续病毒学应答（SVR）（67.7%）。对特定病毒基因型的治疗结果分析表明，在基因型 1 和/或 4 感染者中，包括基因型 1 与基因型 3 重组者，114 例（63.3%）获得 SVR，IDU 组与非 IDU 组之间的 SVR 分布无显著差异（P=0.079）。在感染 HCV 基因型 2 和/或 3 的患者中，SVR 率高达 86.6%。
IDU 合并 CHC 感染应接受标准的 CHC 抗病毒治疗，因为 IDU 患者的治疗成功率与非 IDU 患者相当甚至更好。
